Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura

Overview of attention for article published in Drug Design, Development and Therapy, April 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 41 Dimensions

Readers on

mendeley: 55 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 41 publications that cite this research output.

41

The most recent citing publications are shown below. View all 41 publications that cite this research output on Dimensions.

Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons

Article in Expert Review of Hematology (February 2024)

Plasma cell‐directed therapy strategies in immune‐mediated thrombotic thrombocytopenic purpura (iTTP)

Article in Transfusion (January 2024)

Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study

Article in Clinical and Applied Thrombosis/Hemostasis (January 2024)